Stress-reduction program for newly diagnosed triple-negative breast cancer

This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.

This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.

This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).

This study tests a nurse-led coping and support program for people who recently finished treatment for triple-negative breast cancer. The program is designed to help you manage stress and emotional distress after treatment.

This study tests whether a brief stress-reduction therapy called ACT (Acceptance and Commitment Therapy), combined with your standard chemotherapy, may help your body respond better to cancer treatment. The goal is to see if managing stress improves how well the chemotherapy works.

This trial tests whether a structured exercise program can help women with newly diagnosed triple-negative breast cancer who are getting a specific combination of immunotherapy and chemotherapy. The goal is to see if staying active during treatment improves outcomes and well-being.